We are looking forward to the American Society of Clinical Oncology (ASCO) Annual Meeting, where we will present interim data from our ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) non-Hodgkin #lymphoma. We hope to see you at #ASCO24!
Century Therapeutics, Inc’s Post
More Relevant Posts
-
Today, we announced a poster presentation at the American Society of Clinical Oncology (ASCO)) annual meeting highlighting interim results from the ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) #lymphoma. The poster showcases CNTY-101’s continued encouraging preliminary efficacy and manageable safety profile for with no observed DLTs or GvHD. Learn more: https://bit.ly/3RaEI3k #ASCO2024
To view or add a comment, sign in
-
-
Which #cancers are HCPs talking about online at American Society of Clinical Oncology (ASCO) ? Presentations on studies such as the #CROWN and #PALOMA-3 trials are causing the #lungcancer conversation to dominate. Watch this space for more updates from the next three days of #ASCO24! #WhatHCPsThink
To view or add a comment, sign in
-
-
This new study in BMJ Oncology highlights that despite the known crucial importance of health-related quality of life outcomes, their reporting remains suboptimal. https://lnkd.in/eiT-mcDe
To view or add a comment, sign in
-
-
In this episode of Oncology Today with Dr Neil Love, you can hear the perspectives Dr Petros Grivas shares on research with and ongoing studies evaluating available and investigational agents and strategies for patients with UBC.
Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer
To view or add a comment, sign in
-
ctDNA testing can be used to guide decisions about adjuvant treatment in patients with stage II-III CRC, Pashtoon Kasi reported at American Society of Clinical Oncology (ASCO) #GI24. #ASCOGI24 #gicsm #colorrectalcancer
To view or add a comment, sign in
-
When you are completing an oncology study you need to have new approaches and fresh ideas to overcome the vast complications that can appear – and Stiris is your answer. Our team of clinical research veterans know what it takes to bring oncology studies to success, and regardless of the size of the study you will always get our A team. Want to know more about how Stiris can make your Oncology studies successful? Reach out to us (Info@StirisResearch.com) and we would be happy to share! #OutOfTheBox #ClinicalTrials #OncologyTrials #ClinicalResearch #StirisResearch
To view or add a comment, sign in
-
REMINDER: Don't miss our upcoming webinar on December 5, "Unleashing the Power of Real-World Clinico-Genomic Data in Advancing Precision Oncology," featuring Emily L Paul and Suzzette Arnal. Learn more and register at the link below! #ClinicoGenomics #PrecisionOncology #CGP
Unleashing the Power of Real-World Clinico-Genomic Data in Advancing Precision Oncology
event.on24.com
To view or add a comment, sign in
-
A new read from our team is out in IOVS (Ocular Oncology Special Issue). Not 100 μl, even 1 μl of aqueous humor has implications for clinical testing of retinoblastoma. More insights can be read at https://lnkd.in/gXpa6MNF
To view or add a comment, sign in
-
-
Check out the latest Oncology Insights article from Simone Ndujiuba, PharmD, BCOP as she discusses the key findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Learn more here: https://bit.ly/3SePnKM
To view or add a comment, sign in
-
Oncology specialists outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies. #Oncology #MedEd https://lnkd.in/ery6gh6W
Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
onclive.com
To view or add a comment, sign in
More from this author
-
Spotlight the Night: An Interview with Hy Levitsky, Century's President of R&D and Seattle Light the Night Fundraising Team Lead
Century Therapeutics, Inc 2y -
Spotlight the Night: An Interview with Greg Russotti, Century's CTO and Philadelphia Light the Night Fundraising Team Lead
Century Therapeutics, Inc 2y